Alzheimer’s drug requires strengthened pharmacovigilance approach
European Pharmaceutical Review
MARCH 7, 2025
A paper published by the Drug Safety Research Unit (DSRU) in the British Journal for Clinical Pharmacology , has asserted the need for ongoing assessment of the safety and effectiveness of the Alzheimers drug lecanemab in the real-world clinical setting.
Let's personalize your content